ASCO Annual Meeting | Conference

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

June 7th 2022

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC

June 7th 2022

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

June 7th 2022

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer

June 7th 2022

Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.

Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC

June 7th 2022

Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.

Radiotherapy Unnecessary for Some Luminal A Breast Cancers

June 7th 2022

Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.

Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC

June 7th 2022

Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.

Dostarlimab Elicits Clinical Complete Response Among All Treated Patients with dMMR Rectal Cancer

June 7th 2022

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

Adjuvant Pembrolizumab Demonstrates DFS Benefit in Key Subgroups of Resected Early-Stage NSCLC

June 7th 2022

Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.

Significant Enrichment of CDKN2A/B Alterations Found in Patients With NSCLC and Brain Mets

June 7th 2022

Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.

FOLFOXIRI Plus Bevacizumab Improves PFS, ORR at Expense of Increased Toxicity in CRC Liver Metastases

June 7th 2022

FOLFOXIRI plus bevacizumab led to a significant improvement in progression-free survival, objective response rate, and R0/1 resections vs FOLFOX/FOLFIRI plus bevacizumab but resulted in increased toxicity in patients with initially unresectable colorectal cancer liver metastases and right-sided and/or RAS- or BRAF V600E–mutated primary tumors.

Darolutamide Does Not Affect Cabazitaxel Systemic Exposure in mCRPC

June 7th 2022

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

Lasofoxifene/Abemaciclib Shows Acceptable Safety, Promising Efficacy in Previously Treated, ESR1-Mutated Metastatic Breast Cancer

June 6th 2022

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Ribociclib Shows Superior QOL With Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

June 6th 2022

Ribociclib plus an aromatase inhibitor elicited improved symptom-related quality of life outcomes compared with abemaciclib plus an aromatase inhibitor as first-line therapy in postmenopausal patients with hormone receptor–positive, HER2–negative advanced breast cancer, according to findings from a matching-adjusted indirect comparison study.

Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer

June 6th 2022

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

Dr. Modi on the Findings of DESTINY-Breast04 in HER2-Low Breast Cancer

June 6th 2022

Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.

NEXT PAGE
PREVIOUS PAGE
x